Cargando…

Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19

• Chemotherapy resumption after convalescence from COVID-19 is safe and feasible. • No guidelines exist for resumption of chemotherapy in patients with COVID-19. • Cancer patients on chemotherapy may develop SARS-CoV-2 antibodies less frequently.

Detalles Bibliográficos
Autores principales:	Liontos, Michalis, Kaparelou, Maria, Karofylakis, Emmanouil, Kavatha, Dimitra, Mentis, Andreas, Zagouri, Flora, Terpos, Evangelos, Dimopoulos, Meletios-Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390730/ https://www.ncbi.nlm.nih.gov/pubmed/32766415 http://dx.doi.org/10.1016/j.gore.2020.100615

Ejemplares similares

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021)

Advances in Gynecological Cancers
por: Liontos, Michalis, et al.
Publicado: (2022)

Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature
por: Papatheodoridi, Alkistis, et al.
Publicado: (2023)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021)

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience
por: Liontos, Michalis, et al.
Publicado: (2021)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Subarachnoid hemorrhage in a postpartum mother: A rare manifestation of an uncommon disease
por: Fiste, Oraianthi, et al.
Publicado: (2022)

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
por: Liontos, Michalis, et al.
Publicado: (2014)

Supportive medication in cancer during pregnancy
por: Zagouri, Flora, et al.
Publicado: (2020)

Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature
por: Liontos, Michalis, et al.
Publicado: (2021)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
por: Svarna, Anna, et al.
Publicado: (2023)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: Liontos, M., et al.
Publicado: (2021)

Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer
por: Skafida, Efthymia, et al.
Publicado: (2020)

TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy
por: Korakiti, Anna-Maria, et al.
Publicado: (2020)

Pembrolizumab in endometrial cancer: Where we stand now
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2021)

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
por: Kyriazoglou, Anastasios, et al.
Publicado: (2018)

The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients
por: Labropoulou, Stavroula, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3jkrqfhoue95of1vvm2drqeocb